Lilly’s Olumiant okayed in alopecia, with Pfizer, Concert in hot pursuit
pharmaphorum
JUNE 14, 2022
Eli Lilly and Incyte’s Olumiant has secured the first FDA approval for a systemic drug to treat alopecia areata, an autoimmune condition causing patchy hair loss that affects more than 700,000 people in the US. billion from its approved indications last year. billion from its approved indications last year.
98 
Let's personalize your content